LuciVenet 100 MG (Venetoclax)

Description

Venetoclax

Each film-coated tablet contains: Venetoclax … 100mg

INDICATION

LuciVenet is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In combination with azacitidine, or decitabine, or low -dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

DOSAGE AND USE

5-week ramp-up dosing schedule • Week 1: LuciVenet 20mg once daily • Week 2: LuciVenet 50mg once daily • Week 3: LuciVenet 100mg once daily • Week 4: LuciVenet 200mg once daily • Week 5: LuciVenet 400mg once daily The recommended dosage of LuciVenet is 400 mg once daily after completion of the 5-week ramp-up dosing schedule. Continue LuciVenet until disease progression or unacceptable toxicity. Tablet should be swallowed whole & not chewed or crushed.

STORAGE

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY

LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING

Keep medicine out of the reach of Children. Do not administered LuciVenet in Pregnancy and Lactation patient treatment.